Compare Stocks → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AGLENASDAQ:COGTNASDAQ:EPIXNASDAQ:NEXI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGLEAeglea BioTherapeutics$11.47$2.66▼$32.75$48.64M2.5795,409 shs43,300 shsCOGTCogent Biosciences$7.92+4.2%$6.76$3.67▼$13.50$757.26M1.571.95 million shs1.29 million shsEPIXESSA Pharma$6.25-7.3%$7.91$2.58▼$11.67$276.50M1.76126,134 shs31,946 shsNEXINexImmune$3.46+2.4%$4.64$1.25▼$28.69$4.74M2.031.54 million shs40,839 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGLEAeglea BioTherapeutics0.00%0.00%0.00%0.00%+192.93%COGTCogent Biosciences+4.21%+8.64%+13.30%+34.69%-32.08%EPIXESSA Pharma-7.27%-10.07%-19.15%-40.08%+123.21%NEXINexImmune-0.86%+10.90%-4.42%-60.86%-58.26%“Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACOGTCogent Biosciences2.0406 of 5 stars4.41.00.00.02.40.00.6EPIXESSA Pharma2.1135 of 5 stars3.53.00.00.01.13.30.0NEXINexImmuneN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGLEAeglea BioTherapeutics2.50Moderate Buy$17.50∞ UpsideCOGTCogent Biosciences2.71Moderate Buy$13.6772.56% UpsideEPIXESSA Pharma3.00Buy$16.50164.00% UpsideNEXINexImmuneN/AN/AN/AN/ACurrent Analyst RatingsLatest NEXI, COGT, EPIX, and AGLE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2024COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.002/27/2024COGTCogent BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$18.00 ➝ $20.002/26/2024COGTCogent BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$11.00 ➝ $13.002/26/2024COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.002/26/2024COGTCogent BiosciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$14.00 ➝ $8.002/23/2024COGTCogent BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$5.00 ➝ $10.002/22/2024COGTCogent BiosciencesLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/12/2024COGTCogent BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGLEAeglea BioTherapeutics$2.33M0.00N/AN/A($60.61) per share0.00COGTCogent BiosciencesN/AN/AN/AN/A$2.30 per shareN/AEPIXESSA PharmaN/AN/AN/AN/A$3.30 per shareN/ANEXINexImmuneN/AN/AN/AN/A$3.32 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGLEAeglea BioTherapeutics-$83.82M-$75.59N/AN/AN/A-22,195.36%-132.05%-146.87%N/ACOGTCogent Biosciences-$192.41M-$2.48N/AN/AN/AN/A-86.67%-58.11%8/13/2024 (Estimated)EPIXESSA Pharma-$26.58M-$0.59N/AN/AN/AN/A-17.41%-17.04%5/14/2024 (Estimated)NEXINexImmune-$32.34M-$30.89N/A∞N/AN/A-247.17%-167.39%5/20/2024 (Estimated)Latest NEXI, COGT, EPIX, and AGLE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2024Q1 2024COGTCogent Biosciences-$0.51-$0.62-$0.11-$0.62N/AN/A4/16/2024Q4 2023NEXINexImmuneN/A-$4.99-$4.99-$4.99N/AN/A2/26/202412/31/2023COGTCogent Biosciences-$0.55-$0.63-$0.08-$0.63N/AN/A2/13/202412/31/2023EPIXESSA Pharma-$0.17-$0.14+$0.03-$0.14N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGLEAeglea BioTherapeuticsN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/ANEXINexImmuneN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGLEAeglea BioTherapeuticsN/A4.594.59COGTCogent BiosciencesN/A7.097.09EPIXESSA PharmaN/A40.7440.74NEXINexImmuneN/A1.061.06OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGLEAeglea BioTherapeuticsN/ACOGTCogent BiosciencesN/AEPIXESSA Pharma75.12%NEXINexImmune9.85%Insider OwnershipCompanyInsider OwnershipAGLEAeglea BioTherapeutics6.60%COGTCogent Biosciences5.92%EPIXESSA Pharma14.70%NEXINexImmune19.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAGLEAeglea BioTherapeutics694.05 million3.78 millionOptionableCOGTCogent Biosciences16495.61 million89.95 millionOptionableEPIXESSA Pharma5044.24 million37.74 millionOptionableNEXINexImmune221.37 million1.11 millionNot OptionableNEXI, COGT, EPIX, and AGLE HeadlinesSourceHeadlineSpyre Therapeutics (NASDAQ:SYRE) and NexImmune (NASDAQ:NEXI) Head to Head Contrastamericanbankingnews.com - May 2 at 2:22 AMNanoengineering Approaches to the Design of Artificial Antigen-presenting Cellsmedscape.com - April 20 at 3:38 PMNEXI Stock Earnings: NexImmune Reported Results for Q4 2023investorplace.com - April 17 at 1:03 AMAcute Myeloid Leukemia Market Size is Expected to Grow by 2032 | DelveInsighttheglobeandmail.com - April 16 at 12:07 AMPortage mulls company closure, pauses enrolment for lead clinical programmemsn.com - April 15 at 7:00 PMXilio fires 21% of its workforce and reprioritises pipelinemsn.com - April 2 at 4:55 PMInvestors grapple with more choices in big year for pharma fundraisingpharmaceutical-technology.com - March 20 at 7:15 PMNexImmune Announces New Offerings in Recent Press Releasemsn.com - February 7 at 3:58 PMNexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesmarkets.businessinsider.com - February 6 at 9:13 PMNexImmune Secures Funding Through Equity and Warrant Salesmsn.com - February 6 at 8:39 AMNexImmune Ends Stock Sale Agreement, Raises $5.1 Millionmsn.com - February 3 at 3:23 PMNexImmune slips after securities offeringmsn.com - February 2 at 6:34 PMNexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesfinance.yahoo.com - February 2 at 6:34 PMNexImmune, Inc. Common Stock (NEXI)nasdaq.com - January 13 at 9:31 PMNexImmune (NEXI) Stock Rockets 80% Ahead of Potential Liquidationinvestorplace.com - January 9 at 1:04 PMNeximmune Inc (NEXI) Took The Aerial Rout In The Pre-Market Sessionknoxdaily.com - January 4 at 10:20 AMNexImmune's future in limbo as Gaithersburg biotech extends liquidation votebizjournals.com - December 26 at 2:54 PMNexImmune: Submission Of Matters To A Vote Of Security Holders, Other Eventscbonds.com - December 24 at 8:51 AMNexImmune, Inc. (NEXI) Stock Price, News, Quote & History - Yahoo Financeca.finance.yahoo.com - December 10 at 8:27 PMNexImmune: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listingcbonds.com - December 3 at 8:08 AMNEXI Stock Halted: What’s Going on With NexImmune Shares Today?investorplace.com - December 1 at 2:04 PMWhy Is NexImmune (NEXI) Stock Up 353% Today?investorplace.com - December 1 at 9:12 AMNexImmune Inc Ordinary Shares NEXImorningstar.com - November 23 at 8:51 PMGaithersburg’s NexImmune prepares to shut down, lay off ‘substantially all’ employeesbizjournals.com - November 8 at 6:33 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAeglea BioTherapeuticsNASDAQ:AGLEAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.Cogent BiosciencesNASDAQ:COGTCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.ESSA PharmaNASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.NexImmuneNASDAQ:NEXINexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.